The importance of KRAS status in managing metastatic colorectal cancer
- 35 Downloads
In the past decade, the standard of care for advanced colorectal cancer has been in a state of flux with the introduction of new agents in the treatment of stage IV disease; however, the 5-year survival rate for advanced disease remains low. Investigators are trying to identify biomarkers that may be predictive and/or prognostic for these agents and thereby improve patient outcomes. This article discusses recent discoveries that have identified the importance of KRAS mutational status in predicting responses to epidermal growth factor receptor-targeting antibodies (cetuximab and panitumumab) in the management of metastatic colon cancer.
Unable to display preview. Download preview PDF.
References and Recommended Reading
- 17.Allegra CJ, Jessup JM, Somerfield MR, et al.: American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 2009 (Epub ahead of print).Google Scholar
- 25.Finocchiaro G, Cappuzzo F, Janne PA, et al.: EGFR, HER2 and Kras as predictive factors for cetuximab sensitivity in colorectal cancer [abstract]. J Clin Oncol 2007, 25(Suppl):4021.Google Scholar